2025 年 2 月,《金融时报》发布报道,强生公司(Johnson & Johnson)计划出售旗下中风治疗业务 Cerenovus,估值在 10 亿(约合人民币73亿)至 15 亿美元(约合人民币110亿)之间。消息人士透露,强生已通过顾问与潜在的私募股权及战略买家展开接触,以便了解市场对 Cerenovus 的兴趣程度。目前,强生官方尚未对这一传闻做出直接回应,但从其近年来的战略布局来看,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.